Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Tuberculosis

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Successful treatment with joint retention of Mycobacterium ulcerans prosthetic joint infection in a patient with rheumatoid arthritis.

PLoS neglected tropical diseases·2025

Same author

Buruli ulcer.

Nature reviews. Disease primers·2025

Same author

Defining new Buruli ulcer endemic areas in urban southeastern Australia using bacterial genomics-informed possum excreta surveys.

Applied and environmental microbiology·2025

Same author

Performance of the Australian hospital-acquired complication algorithm for detecting hospital-onset bloodstream infections.

Infection, disease & health·2025

Same author

Perceptions of a Buruli ulcer controlled human infection model: How, who, and why?

PLoS neglected tropical diseases·2025

Same author

Buruli ulcer in Australia: Evidence for a new endemic focus at Batemans Bay, New South Wales.

PLoS neglected tropical diseases·2024

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Analysis of ¹⁸FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Extensively resistant tuberculosis in the lands Down Under.

Paul D R Johnson

The Medical Journal of Australia

|June 8, 2011

Summary

This summary is machine-generated.

Managing tuberculosis is becoming exponentially more costly and complex as drug resistance increases. This trend highlights the urgent need for new treatment strategies to combat rising antimicrobial resistance in tuberculosis cases.

Related Experiment Videos

Last Updated: Jun 1, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Analysis of ¹⁸FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Area of Science:

Microbiology
Epidemiology
Health Economics

Background:

Tuberculosis (TB) remains a significant global health challenge.
Increasing rates of drug-resistant tuberculosis (DR-TB) complicate treatment regimens.
Linear increases in antimicrobial resistance correlate with exponential rises in management costs and complexity.

Discussion:

The economic burden of DR-TB necessitates innovative and cost-effective interventions.
Linear progression of resistance does not equate to linear cost increases; management complexity drives exponential cost growth.
Understanding the drivers of this exponential cost increase is crucial for resource allocation and policy development.

Key Insights:

Antimicrobial resistance in tuberculosis is a growing threat.
The cost and complexity of managing drug-resistant tuberculosis escalate disproportionately with resistance levels.
Effective strategies are needed to mitigate the financial and logistical challenges posed by DR-TB.

Outlook:

Future research should focus on novel diagnostics and therapeutics for DR-TB.
Policy interventions must address the economic impact of escalating resistance.
Global collaboration is essential to control the spread of drug-resistant tuberculosis and manage its associated costs.